Compare CP & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CP | MRNA |
|---|---|---|
| Founded | 1881 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0B | 91.2B |
| IPO Year | 2000 | 2018 |
| Metric | CP | MRNA |
|---|---|---|
| Price | $93.98 | $247.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 31 | 23 |
| Target Price | $97.98 | ★ $154.47 |
| AVG Volume (30 Days) | 2.3M | ★ 14.2M |
| Earning Date | 10-28-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | 13.32 | ★ 21.77 |
| EPS | ★ 3.14 | N/A |
| Revenue | $15,078,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $9.77 | $22.23 |
| Revenue Next Year | $6.37 | $11.63 |
| P/E Ratio | $29.86 | ★ N/A |
| Revenue Growth | 3.66 | ★ 4.29 |
| 52 Week Low | $68.83 | $22.28 |
| 52 Week High | $96.90 | $280.80 |
| Indicator | CP | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 58.77 |
| Support Level | $87.30 | $45.39 |
| Resistance Level | $96.90 | $254.48 |
| Average True Range (ATR) | 2.10 | 20.18 |
| MACD | 0.43 | 1.45 |
| Stochastic Oscillator | 83.75 | 68.94 |
Canadian Pacific Kansas City is a Class I railroad operating on tracks that span most of Canada and into parts of the Midwestern and Northeastern United States. Following the April 2023 Kansas City Southern merger, CPKC operates new single-linehaul services from Canada and the Upper Midwest down through Texas, the Gulf of Mexico, and into Mexico. It also hauls cross-border and intra-Mexico freight via operating concessions on more than 3,000 miles of rail in Mexico. CPKC hauls shipments of grain, intermodal containers, energy products (like crude and frac sand), chemicals, plastics, coal, fertilizer and potash, automotive products, and a diverse mix of other merchandise.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.